Astria Therapeutics, Inc. (ATXS) Misses Q4 EPS by 3c

Astria Therapeutics, Inc. (NASDAQ: ATXS) reported Q4 EPS of ($0.72), $0.03 worse than the analyst estimate of ($0.69).

For earnings history and earnings-related data on Astria Therapeutics, Inc. (ATXS) click here.

You May Also Be Interested In

• Abercrombie & Fitch (ANF) Tops Q2 EPS by $2.19, Offers Guidance
• Zhihu Inc. (ZH) Reports Q2 Revenue Below Estimates
• Meta to pay $18 billion over 10 years for youth online safety initiatives.